American Oncology Network (AONC) Total Debt to Capital

American Oncology Network - graphic logo of issuer AONC

This price visualization for American Oncology Network (AONC) debt load is at 0.00, highlighting the risks of narrow specialization in US regional centers and attempts to optimize profits through pharmacy digitalization. The business relies on a steady patient inflow, guaranteeing predictable revenue. Meanwhile, American Oncology Network (AONC) delegates its IT infrastructure and accounting to external contractors while maintaining direct control over its medical staff.

American Oncology Network Inc (AONC): Debt to Equity Ratio from 02/21/2024 to 08/04/2024
Finished products of American Oncology Network Inc

American Oncology Network leverages its regional clinic dominance and procurement pricing power to effectively manage margins. By analyzing the trend of the company's total liabilities-to-equity ratio, an investor assesses the business's leverage by comparing total debt with equity, which determines the financial stability and debt load risk for this asset class.

Competitor analysis for American Oncology Network

ONC (BeiGene) - Total Debt to Capital|Total Debt to Equity Ratio Halozyme Therapeutics, Inc. (HALO)|Total Debt to Capital RVMD|Total Debt to Capital Ascentage Pharma Corp (AAPG)|Debt to Equity CG Oncology, Inc. CGON|URGN: Debt to Equity Ratio|Bicara Therapeutics - Total Debt to Capital|Personalis Inc (PSNL) - Total Debt to Equity Ratio|ERAS: Total Debt to Capital|Debt to Capital Delcath Corp (DCTH)|Debt to Equity Y-mAbs Therapeutics|AURA: All Debt to Shareholders' Equity Ratio|Total Debt to Equity Ratio CADL (Candel Therapeutics)|ARAY (Accuray Inc) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital SLS (SELLAS Life Sciences Group)|ACTU - Total Debt to Equity Ratio|CTOR: Total Debt to Equity Ratio|HURA - Total Debt to Capital|Protara Therapeutics, Inc. (TARA) - Debt to Equity|Fate Therapeutics Inc - All Debt to Shareholders' Equity Ratio|WHWK (Aadi Bioscience, Inc.) - Total Debt to Capital|Debt to Capital TScan TCRX|Total Debt to Capital CSBR|Total Debt to Capital xbiotech.com (XBIT)|Debt to Equity CEL-SCI CVM|OSTX - Total Debt to Equity Ratio|Radiopharm Theranostics Limited - Total Debt to Capital|Debt to Capital Artiva Biotherapeutics, Inc.|adlainortye.com (ANL) - Debt to Equity|verupharma.com - All Debt to Shareholders' Equity Ratio|TPST (Tempest Therapeutics, Inc.) - Total Debt to Capital|Xilio (XLO) - Total Debt to Capital Coefficient|Total Debt to Capital RENB|Total Debt to Equity Ratio muraloncology.com MURA|Total Debt to Capital KAPA (Kairos Pharma)|Total Debt to Capital OnKure Therapeutics, Inc. OKUR|GDTC - Debt to Equity|CRIS (Curis, Inc.) - Debt to Equity Ratio|APLM (apollomicsinc.com) - Total Debt to Equity Ratio|Tharimmune Corporation - All Debt to Shareholders' Equity Ratio|Debt to Equity Advanced Biomed Inc.|Debt to Capital genprex.com GNPX|Debt to Equity Calidi Biotherapeutics (CLDI)|Sunshine Biopharma Inc. - Debt to Equity Ratio|Total Debt to Capital XBIO (Xenetic Biosciences, Inc.)|SLRX - Total Debt to Equity Ratio|PPBT - Debt to Equity|Debt to Capital beigene.com|Checkpoint Therapeutics, Inc. (CKPT) - Debt to Equity|ELEV (elevationoncology.com) - Debt to Equity|Debt to Equity iCAD Inc.|Debt to Capital Ikena IKNA|Total Debt to Capital NTBL|viracta.com (VIRX) - Debt to Capital Ratio|MorphoSys - Total Debt to Equity Ratio|NAYA Biosciences Inc (NAYA) - Debt to Capital|AAPGV: Total Debt to Equity Ratio